本文へ移動
cccskills
無料GitHub で公開

endo-assess-cgm-site-selection-care

Evaluates patient’s selection of sensor insertion sites and site care to prevent irritation or infection. Triggers include: 'Review CGM site rotation', 'Check sensor site hygiene and adhesion'.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Assess CGM site selection and care

STEP 1 — Gather Information

Collect data on current CGM site(s), duration of use, skin condition (redness, itching, infection, induration), adhesion quality, rotation pattern, patient hygiene practices, understanding of site selection, any adhesive allergies, and use of skin prep or barrier products.

STEP 2 — Rule In / Rule Out

Determine if there are signs of site‑related complications (persistent erythema, induration, purulent discharge, lipohypertrophy, or frequent sensor loss due to poor adhesion). If present, rule in a site issue; if absent, rule out.

STEP 3 — Classify or Stratify

Classify site adequacy as: Adequate (no complications, proper rotation, good adhesion), Marginal (mild irritation, occasional adhesion failure, suboptimal rotation), or Inadequate (significant skin breakdown, infection, repeated sensor failures attributable to the site).

STEP 4 — Decide

  • Adequate: Reinforce current practice and schedule routine reassessment at next visit or per Table 2 annual review.
  • Marginal: Provide targeted education on skin preparation (clean with mild soap/water, dry fully), proper rotation (≥2 weeks between uses), and adhesive use; consider a skin‑tac barrier or hypoallergenic tape.
  • Inadequate: Discontinue CGM use at the affected site, allow skin to heal, educate on alternative sites and proper care, and re‑initiate CGM only after resolution and with a revised site‑selection plan.

Clinical Guardrails / Mimics / Pitfalls

Do not ignore mild erythema as it can progress to infection; avoid alcohol wipes immediately before insertion if they cause dryness; do not reuse a site without adequate healing time (≥2 weeks); avoid placing sensors over lipohypertrophy, scar tissue, or bony prominences; do not rely solely on patient self‑report without visual inspection of the site.

Concrete Clinical Example

A 58‑year‑old with type 1 diabetes reports frequent sensor detachment and mild itching at the abdomen site used for the past 6 weeks. Assessment shows localized erythema without drainage and adhesion failure after 3 days. Classified as Marginal. Intervention: educated on cleaning with mild soap/water, drying fully, applying a thin barrier wipe, rotating to the upper buttock, and using a skin‑tac adhesive patch. Sensor re‑inserted at the new site with no detachment or irritation at 1‑week follow‑up.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, https://doi.org/10.1210/jc.2016-2534

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する